Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
SKYE BIOSCIENCE, INC. |
Delayed
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 4 USD | +14.29% | +124.72% | -1.23% | |
Financials (USD)
| Sales 2022 * | - | Sales 2023 * | - | Capitalization | 14.8M |
|---|---|---|---|---|---|
| Net income 2022 | -19M | Net income 2023 * | - | EV / Sales 2022 | - |
| Net Debt 2022 | 738K | Net cash position 2023 * | - | EV / Sales 2023 * | - |
| P/E ratio 2022 | -0,41x | P/E ratio 2023 * | Employees | 11 | |
| Yield 2022 | - | Yield 2023 * |
-
| Free-Float | 83.93% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +12.57% | ||
| 1 week | +121.35% | ||
| Current month | +144.72% | ||
| 1 month | +131.76% | ||
| 3 months | +57.60% | ||
| 6 months | -0.57% | ||
| Current year | -2.72% |
1 week
2.43
4.45
1 month
1.444.45
Current year
1.4414.00
1 year
1.4414.00
3 years
1.4464.73
5 years
1.44292.50
10 years
1.442 750.00
| Managers | Title | Age | Since |
|---|---|---|---|
Punit Dhillon
CEO | Chief Executive Officer | 43 | 2018 |
| Director of Finance/CFO | - | 2021 | |
| Chief Tech/Sci/R&D Officer | 51 | Dec. 12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 76 | 2020 | |
Praveen Tyle
BRD | Director/Board Member | 63 | 2021 |
Punit Dhillon
CEO | Chief Executive Officer | 43 | 2018 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-11 | 4 | +14.29% | 23 290 |
| 23-12-08 | 3.5 | -17.06% | 27,133 |
| 23-12-07 | 4.22 | +5.24% | 35,281 |
| 23-12-06 | 4.01 | +41.20% | 60,014 |
| 23-12-05 | 2.84 | +59.55% | 21,355 |
Delayed Quote OTC Markets, December 11, 2023 at 12:14 pm EST
More quotes
Skye Bioscience Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of a class of cannabinoid derivatives to modulate the endocannabinoid system. The Company develops cannabinoid derivatives that have the potential to treat ophthalmic disorders and other diseases with unmet needs. The Company's lead product candidate, SBI-100 OE, is being developed for the treatment of glaucoma and ocular hypertension. The first-in-human Phase I trial of SBI-100 OE is being conducted in healthy volunteers in Australia to evaluate this drug candidate's safety, tolerability, pharmacokinetics and pharmacodynamics. It is also focused on developing different formulations of SBI-200. Early studies of SBI-200 demonstrated analgesic, anti- inflammatory, anti-fibrotic and anti-seizure properties, including the potential treatment and management of several eye diseases, such as uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.
| 1st Jan change | Capi. | |
|---|---|---|
| -2.72% | 43 M $ | |
| +71.69% | 41 313 M $ | |
| +5.68% | 39 289 M $ | |
| -54.20% | 30 625 M $ | |
| -28.27% | 27 758 M $ | |
| +41.25% | 22 431 M $ | |
| -27.90% | 21 339 M $ | |
| +10.72% | 17 693 M $ | |
| -12.93% | 11 356 M $ | |
| -16.81% | 10 803 M $ |
